Cargando…

Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia

Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to...

Descripción completa

Detalles Bibliográficos
Autores principales: Bou-Tayeh, Berna, Laletin, Vladimir, Salem, Nassim, Just-Landi, Sylvaine, Fares, Joanna, Leblanc, Raphael, Balzano, Marielle, Kerdiles, Yann M., Bidaut, Ghislain, Hérault, Olivier, Olive, Daniel, Aurrand-Lions, Michel, Walzer, Thierry, Nunès, Jacques A., Fauriat, Cyril
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718679/
https://www.ncbi.nlm.nih.gov/pubmed/34975835
http://dx.doi.org/10.3389/fimmu.2021.730970
_version_ 1784624780257787904
author Bou-Tayeh, Berna
Laletin, Vladimir
Salem, Nassim
Just-Landi, Sylvaine
Fares, Joanna
Leblanc, Raphael
Balzano, Marielle
Kerdiles, Yann M.
Bidaut, Ghislain
Hérault, Olivier
Olive, Daniel
Aurrand-Lions, Michel
Walzer, Thierry
Nunès, Jacques A.
Fauriat, Cyril
author_facet Bou-Tayeh, Berna
Laletin, Vladimir
Salem, Nassim
Just-Landi, Sylvaine
Fares, Joanna
Leblanc, Raphael
Balzano, Marielle
Kerdiles, Yann M.
Bidaut, Ghislain
Hérault, Olivier
Olive, Daniel
Aurrand-Lions, Michel
Walzer, Thierry
Nunès, Jacques A.
Fauriat, Cyril
author_sort Bou-Tayeh, Berna
collection PubMed
description Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond to IL-15 stimulation in vitro as illustrated by reduced activation of the mTOR pathway. Moreover, our data suggest that mTOR-mediated metabolic responses were reduced in NK cells from AML-bearing mice. Noteworthy, the reduction of mTOR-mediated activation of NK cells during AML development partially rescued NK cell metabolic and functional defects. Altogether, our data strongly suggest that NK cells from leukemic mice are metabolically and functionally exhausted as a result of a chronic cytokine activation, at least partially IL-15/mTOR signaling. NK cells from AML patients also displayed reduced IL-2/15Rβ expression and showed cues of reduced metabolic response to IL-15 stimulation in vitro, suggesting that a similar mechanism might occur in AML patients. Our study pinpoints the dysregulation of cytokine stimulation pathways as a new mechanism leading to NK cell defects in AML.
format Online
Article
Text
id pubmed-8718679
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87186792022-01-01 Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia Bou-Tayeh, Berna Laletin, Vladimir Salem, Nassim Just-Landi, Sylvaine Fares, Joanna Leblanc, Raphael Balzano, Marielle Kerdiles, Yann M. Bidaut, Ghislain Hérault, Olivier Olive, Daniel Aurrand-Lions, Michel Walzer, Thierry Nunès, Jacques A. Fauriat, Cyril Front Immunol Immunology Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond to IL-15 stimulation in vitro as illustrated by reduced activation of the mTOR pathway. Moreover, our data suggest that mTOR-mediated metabolic responses were reduced in NK cells from AML-bearing mice. Noteworthy, the reduction of mTOR-mediated activation of NK cells during AML development partially rescued NK cell metabolic and functional defects. Altogether, our data strongly suggest that NK cells from leukemic mice are metabolically and functionally exhausted as a result of a chronic cytokine activation, at least partially IL-15/mTOR signaling. NK cells from AML patients also displayed reduced IL-2/15Rβ expression and showed cues of reduced metabolic response to IL-15 stimulation in vitro, suggesting that a similar mechanism might occur in AML patients. Our study pinpoints the dysregulation of cytokine stimulation pathways as a new mechanism leading to NK cell defects in AML. Frontiers Media S.A. 2021-12-17 /pmc/articles/PMC8718679/ /pubmed/34975835 http://dx.doi.org/10.3389/fimmu.2021.730970 Text en Copyright © 2021 Bou-Tayeh, Laletin, Salem, Just-Landi, Fares, Leblanc, Balzano, Kerdiles, Bidaut, Hérault, Olive, Aurrand-Lions, Walzer, Nunès and Fauriat https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Bou-Tayeh, Berna
Laletin, Vladimir
Salem, Nassim
Just-Landi, Sylvaine
Fares, Joanna
Leblanc, Raphael
Balzano, Marielle
Kerdiles, Yann M.
Bidaut, Ghislain
Hérault, Olivier
Olive, Daniel
Aurrand-Lions, Michel
Walzer, Thierry
Nunès, Jacques A.
Fauriat, Cyril
Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia
title Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia
title_full Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia
title_fullStr Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia
title_full_unstemmed Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia
title_short Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia
title_sort chronic il-15 stimulation and impaired mtor signaling and metabolism in natural killer cells during acute myeloid leukemia
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718679/
https://www.ncbi.nlm.nih.gov/pubmed/34975835
http://dx.doi.org/10.3389/fimmu.2021.730970
work_keys_str_mv AT boutayehberna chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT laletinvladimir chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT salemnassim chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT justlandisylvaine chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT faresjoanna chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT leblancraphael chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT balzanomarielle chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT kerdilesyannm chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT bidautghislain chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT heraultolivier chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT olivedaniel chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT aurrandlionsmichel chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT walzerthierry chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT nunesjacquesa chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia
AT fauriatcyril chronicil15stimulationandimpairedmtorsignalingandmetabolisminnaturalkillercellsduringacutemyeloidleukemia